NGM Bio to re­vert to pri­vate com­pa­ny as MASH po­ten­tial re­mains un­clear

Six­teen years af­ter an­nounc­ing it led NGM Bio’s $25.5 mil­lion Se­ries A, biotech in­vestor The Col­umn Group now plans to take the drug de­vel­op­ment com­pa­ny pri­vate.

TCG is NGM Bio’s largest stock­hold­er, with about 26% of out­stand­ing shares. A spe­cial com­mit­tee of NGM’s board de­ter­mined the take-pri­vate deal is in the “best in­ter­ests” of stock­hold­ers, per a Mon­day morn­ing press re­lease.

At $1.55 per share, the cash deal would give NGM an eq­ui­ty val­ue of $135.0 mil­lion. At the end of 2023, the biotech’s es­ti­mat­ed cash, cash equiv­a­lents and short-term mar­ketable se­cu­ri­ties were $144.2 mil­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER